Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers

被引:10
|
作者
Azzalini, Eros [1 ]
Stanta, Giorgio [1 ]
Canzonieri, Vincenzo [1 ,2 ]
Bonin, Serena [1 ]
机构
[1] Univ Trieste, Dept Med Sci DSM, I-34149 Trieste, Italy
[2] Aviano Natl Canc Inst, Ctr Riferimento Oncol CRO IRCCS, Pathol Unit, I-33081 Pordenone, Italy
关键词
HGSOC; intratumor heterogeneity; SET; classic; clonal evolution; TME; CIN; PLATINUM RESISTANCE; GERMLINE MUTATION; INVASION PATTERNS; CARCINOMA; REVEALS; MICROENVIRONMENT; CLASSIFICATION; MACROPHAGES; RECURRENCE; MORPHOLOGY;
D O I
10.3390/ijms242015077
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and complex genomic state, characterized by high intratumor heterogeneity (ITH) due to chromosomal instability that distinguishes HGSOCs. Histologically, these cancers exhibit significant morphological diversity both within and between tumors. The histologic patterns associated with solid, endometrioid, and transitional (SET) and classic subtypes of HGSOCs offer prognostic insights and may indicate specific molecular profiles. The evolution of HGSOC from primary to metastasis is typically characterized by clonal ITH, involving shared or divergent mutations in neoplastic sub-clones within primary and metastatic sites. Disease progression and therapy resistance are also influenced by non-clonal ITH, related to interactions with the tumor microenvironment and further genomic changes. Notably, significant alterations occur in nonmalignant cells, including cancer-associated fibroblast and immune cells, during tumor progression. This review provides an overview of the complex nature of HGSOC, encompassing its various aspects of intratumor heterogeneity, histological patterns, and its dynamic evolution during progression and therapy resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers
    Azzalini, Eros
    Barbazza, Renzo
    Stanta, Giorgio
    Giorda, Giorgio
    Bortot, Lucia
    Bartoletti, Michele
    Puglisi, Fabio
    Canzonieri, Vincenzo
    Bonin, Serena
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 498 - 505
  • [2] High-grade serous ovarian cancer: the clone wars
    Salomon-Perzynski, Aleksander
    Salomon-Perzynska, Magdalena
    Michalski, Bogdan
    Skrzypulec-Plinta, Violetta
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
  • [3] Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer
    Lambrechts, Sandrina
    Smeets, Dominiek
    Moisse, Matthieu
    Braicu, Elena Ioana
    Vanderstichele, Adriaan
    Zhao, Hui
    Van Nieuwenhuysen, Els
    Berns, Els
    Sehouli, Jalid
    Zeillinger, Robert
    Darb-Esfahani, Silvia
    Castillo-Tong, Dan Cacsire
    Lambrechts, Diether
    Vergote, Ignace
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 51 - 64
  • [4] Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
    Schwarz, Roland F.
    Ng, Charlotte K. Y.
    Cooke, Susanna L.
    Newman, Scott
    Temple, Jillian
    Piskorz, Anna M.
    Gale, Davina
    Sayal, Karen
    Murtaza, Muhammed
    Baldwin, Peter J.
    Rosenfeld, Nitzan
    Earl, Helena M.
    Sala, Evis
    Jimenez-Linan, Mercedes
    Parkinson, Christine A.
    Markowetz, Florian
    Brenton, James D.
    PLOS MEDICINE, 2015, 12 (02)
  • [5] High-grade Anaplastic Transformation of Ovarian Serous Borderline Tumor
    Zhang, Xiaoming
    Devereaux, Kelly A.
    Ryan, Emily
    Fei, Fei
    Kunder, Christian A.
    Longacre, Teri A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024, 48 (11) : 1395 - 1407
  • [6] Effect of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer
    Wang, Tingjie
    Tian, Lingxi
    Wei, Bing
    Li, Jun
    Zhang, Cuiyun
    Long, Ruitao
    Zhu, Xiaofei
    Zhang, Yougai
    Wang, Bo
    Tang, Guangbo
    Yang, Jun
    Guo, Yongjun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [8] Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women
    Filippova, Olga T.
    Selenica, Pier
    Pareja, Fresia
    Vahdatinia, Mahsa
    Zhu, Yingjie
    Pei, Xin
    Riaz, Nadeem
    Roche, Kara Long
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Ellenson, Lora H.
    Reis-Filho, Jorge S.
    Zamarin, Dmitriy
    Weigelt, Britta
    GYNECOLOGIC ONCOLOGY, 2021, 161 (02) : 545 - 552
  • [9] Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
    Neal, Adam
    Lai, Tiffany
    Singh, Tanya
    Rahseparian, Neela
    Grogan, Tristan
    Elashoff, David
    Scott, Peter
    Pellegrini, Matteo
    Memarzadeh, Sanaz
    CANCERS, 2021, 13 (23)
  • [10] AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
    Azzalini, Eros
    Tierno, Domenico
    Bartoletti, Michele
    Barbazza, Renzo
    Giorda, Giorgio
    Puglisi, Fabio
    Cecere, Sabrina Chiara
    Losito, Nunzia Simona
    Russo, Daniela
    Stanta, Giorgio
    Canzonieri, Vincenzo
    Bonin, Serena
    CANCERS, 2022, 14 (02)